Bellevue Group’s Puma Biotechnology PBYI Stock Holding History

Bellevue Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17,100	Closed	-$663K	–	211
2019 Q1	$663K	Buy	+17,100	New	+$522K	0.04%	132

Other funds holding PBYI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bellevue Group's PBYI Position: Q2 2019 in Review

Bellevue Group sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 17,100 shares — an estimated $663K sold.

Bellevue Group first reported a position in PBYI in Q1 2019 and held it in 1 quarter. The position peaked at $663K in Q1 2019. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

Bellevue Group reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
Bellevue Group sold 17,100 Puma Biotechnology shares in Q2 2019, an estimated $663K.
Bellevue Group first reported a position in Puma Biotechnology in Q1 2019 and held it in 1 quarter.
Bellevue Group's Puma Biotechnology position peaked at $663K in Q1 2019.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.